Cargando…

High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations

BACKGROUND: Acute complications, such as venous thromboembolism (VTE), are common in patients with advanced severe lung cancers. However, current VTE risk scores cannot adequately identify high-risk patients with non-small cell lung cancer (NSCLC). The study proposed to elucidated the incidence of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yiwei, Wang, Wanying, Wu, Fengying, Gao, Guanghui, Xu, Jian, Li, Xuefei, Zhao, Chao, Yang, Shuo, Mao, Shiqi, Pan, Yingying, Jia, Keyi, Shao, Chuchu, Chen, Bin, Ren, Shengxiang, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044490/ https://www.ncbi.nlm.nih.gov/pubmed/33889526 http://dx.doi.org/10.21037/tlcr-20-1290

Ejemplares similares

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer
por: Yu, Xiaofei, et al.
Publicado: (2021)

Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
por: Mao, Shiqi, et al.
Publicado: (2023)

Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
por: Yang, Shuo, et al.
Publicado: (2021)

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
por: Pan, Yingying, et al.
Publicado: (2019)

Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy
por: Shao, Chuchu, et al.
Publicado: (2021)

Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer
por: Dong, Zhengwei, et al.
Publicado: (2020)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
por: Jiang, Tao, et al.
Publicado: (2018)

Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
por: Mao, Shiqi, et al.
Publicado: (2023)

Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy
por: Zhang, Ling, et al.
Publicado: (2012)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway
por: Zhou, Fei, et al.
Publicado: (2023)

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection
por: Shi, Jinpeng, et al.
Publicado: (2021)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes
por: Jiang, Tao, et al.
Publicado: (2020)

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion
por: Qiao, Meng, et al.
Publicado: (2020)

Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis
por: Jiang, Tao, et al.
Publicado: (2015)

Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
por: Jiang, Tao, et al.
Publicado: (2017)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
por: Pan, Hui, et al.
Publicado: (2016)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer
por: Chen, Xiaoxia, et al.
Publicado: (2020)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

The role of endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes
por: Gu, Ye, et al.
Publicado: (2017)

Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2016)

Multi-cancer blood testing combined with PET-CT: road for hope to screen for cancer and guide intervention
por: Jiang, Tao, et al.
Publicado: (2020)

Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors
por: Liu, Sangtian, et al.
Publicado: (2020)

PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Sun, Chenglong, et al.
Publicado: (2020)

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
por: Xu, Qinghua, et al.
Publicado: (2019)

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
por: Jiang, Tao, et al.
Publicado: (2017)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
por: Jiang, Tao, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Serum Levels of the Cancer-Testis Antigen POTEE and Its Clinical Significance in Non-Small-Cell Lung Cancer
por: Wang, Qi, et al.
Publicado: (2015)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
por: Zhou, Juan, et al.
Publicado: (2019)

Thrombotic Events Associated to Aspirin Therapy
por: Doutremepuich, Christian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_51alat9jajl7938vh7kib6i7ns